APO Research
Talk to an analyst

APO RESEARCH · REPORT

Idiopathic Hypersomnia Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Idiopathic Hypersomnia Treatment Market Analysis and Forecast 2026-2032

30 December 2025192 pages

Choose your research edition.

Industry ResearchIdiopathic Hypersomnia Treatment Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Idiopathic Hypersomnia Treatment Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Idiopathic Hypersomnia Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Idiopathic Hypersomnia Treatment Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Idiopathic Hypersomnia Treatment Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Idiopathic Hypersomnia Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Idiopathic Hypersomnia Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Idiopathic Hypersomnia Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Idiopathic Hypersomnia Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Idiopathic Hypersomnia Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Idiopathic Hypersomnia Treatment include Avadel Pharmaceuticals, BIOPROJET, Drive DeVilbiss Healthcare, Fisher and Paykel Healthcare, Jazz Pharmaceuticals, Theranexus, GlaxoSmithKline, Pfizer and Merck, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Idiopathic Hypersomnia Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Idiopathic Hypersomnia Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Idiopathic Hypersomnia Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Idiopathic Hypersomnia Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Idiopathic Hypersomnia Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Idiopathic Hypersomnia Treatment revenue, projected growth trends, production technology, application and end-user industry.

Idiopathic Hypersomnia Treatment Segment by Company

Avadel Pharmaceuticals

BIOPROJET

Drive DeVilbiss Healthcare

Fisher and Paykel Healthcare

Jazz Pharmaceuticals

Theranexus

GlaxoSmithKline

Pfizer

Merck

Teva Pharmaceutical Industries

Takeda Pharmaceutical

Idiopathic Hypersomnia Treatment Segment by Type

Stimulant Medications

Non-Stimulant Wake-Promoting Medications

Sodium Oxybate

Idiopathic Hypersomnia Treatment Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Idiopathic Hypersomnia Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Idiopathic Hypersomnia Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Idiopathic Hypersomnia Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Idiopathic Hypersomnia Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Idiopathic Hypersomnia Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Idiopathic Hypersomnia Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Idiopathic Hypersomnia Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Idiopathic Hypersomnia Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Stimulant Medications Major Player Table 3. Non-Stimulant Wake-Promoting Medications Major Player Table 4. Sodium Oxybate Major Player Table 5. Global Idiopathic Hypersomnia Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Retail Pharmacies Major Player Table 7. Online Pharmacies Major Player Table 8. Hospital Pharmacies Major Player Table 9. Idiopathic Hypersomnia Treatment Industry Trends Table 10. Idiopathic Hypersomnia Treatment Industry Drivers Table 11. Idiopathic Hypersomnia Treatment Industry Opportunities and Challenges Table 12. Idiopathic Hypersomnia Treatment Industry Restraints Table 13. Global Idiopathic Hypersomnia Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Idiopathic Hypersomnia Treatment Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Idiopathic Hypersomnia Treatment Market Share by Region (2021-2026) Table 16. Global Idiopathic Hypersomnia Treatment Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Idiopathic Hypersomnia Treatment Market Share by Region (2027-2032) Table 18. Global Idiopathic Hypersomnia Treatment Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Idiopathic Hypersomnia Treatment Revenue Market Share by Players (2021-2026) Table 20. Global Idiopathic Hypersomnia Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Idiopathic Hypersomnia Treatment Key Players Headquarters & Area Served Table 22. Global Idiopathic Hypersomnia Treatment Players, Product Type & Application Table 23. Global Idiopathic Hypersomnia Treatment Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Idiopathic Hypersomnia Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Idiopathic Hypersomnia Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Idiopathic Hypersomnia Treatment Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Idiopathic Hypersomnia Treatment Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Idiopathic Hypersomnia Treatment Revenue Market Share by Type (2021-2026) Table 30. Global Idiopathic Hypersomnia Treatment Revenue Market Share by Type (2027-2032) Table 31. Global Idiopathic Hypersomnia Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Idiopathic Hypersomnia Treatment Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Idiopathic Hypersomnia Treatment Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Idiopathic Hypersomnia Treatment Revenue Market Share by Application (2021-2026) Table 35. Global Idiopathic Hypersomnia Treatment Revenue Market Share by Application (2027-2032) Table 36. Avadel Pharmaceuticals Company Information Table 37. Avadel Pharmaceuticals Business Overview Table 38. Avadel Pharmaceuticals Idiopathic Hypersomnia Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Avadel Pharmaceuticals Idiopathic Hypersomnia Treatment Product Portfolio Table 40. Avadel Pharmaceuticals Recent Development Table 41. BIOPROJET Company Information Table 42. BIOPROJET Business Overview Table 43. BIOPROJET Idiopathic Hypersomnia Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. BIOPROJET Idiopathic Hypersomnia Treatment Product Portfolio Table 45. BIOPROJET Recent Development Table 46. Drive DeVilbiss Healthcare Company Information Table 47. Drive DeVilbiss Healthcare Business Overview Table 48. Drive DeVilbiss Healthcare Idiopathic Hypersomnia Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Drive DeVilbiss Healthcare Idiopathic Hypersomnia Treatment Product Portfolio Table 50. Drive DeVilbiss Healthcare Recent Development Table 51. Fisher and Paykel Healthcare Company Information Table 52. Fisher and Paykel Healthcare Business Overview Table 53. Fisher and Paykel Healthcare Idiopathic Hypersomnia Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Fisher and Paykel Healthcare Idiopathic Hypersomnia Treatment Product Portfolio Table 55. Fisher and Paykel Healthcare Recent Development Table 56. Jazz Pharmaceuticals Company Information Table 57. Jazz Pharmaceuticals Business Overview Table 58. Jazz Pharmaceuticals Idiopathic Hypersomnia Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Jazz Pharmaceuticals Idiopathic Hypersomnia Treatment Product Portfolio Table 60. Jazz Pharmaceuticals Recent Development Table 61. Theranexus Company Information Table 62. Theranexus Business Overview Table 63. Theranexus Idiopathic Hypersomnia Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Theranexus Idiopathic Hypersomnia Treatment Product Portfolio Table 65. Theranexus Recent Development Table 66. GlaxoSmithKline Company Information Table 67. GlaxoSmithKline Business Overview Table 68. GlaxoSmithKline Idiopathic Hypersomnia Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. GlaxoSmithKline Idiopathic Hypersomnia Treatment Product Portfolio Table 70. GlaxoSmithKline Recent Development Table 71. Pfizer Company Information Table 72. Pfizer Business Overview Table 73. Pfizer Idiopathic Hypersomnia Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Pfizer Idiopathic Hypersomnia Treatment Product Portfolio Table 75. Pfizer Recent Development Table 76. Merck Company Information Table 77. Merck Business Overview Table 78. Merck Idiopathic Hypersomnia Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Merck Idiopathic Hypersomnia Treatment Product Portfolio Table 80. Merck Recent Development Table 81. Teva Pharmaceutical Industries Company Information Table 82. Teva Pharmaceutical Industries Business Overview Table 83. Teva Pharmaceutical Industries Idiopathic Hypersomnia Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Teva Pharmaceutical Industries Idiopathic Hypersomnia Treatment Product Portfolio Table 85. Teva Pharmaceutical Industries Recent Development Table 86. Takeda Pharmaceutical Company Information Table 87. Takeda Pharmaceutical Business Overview Table 88. Takeda Pharmaceutical Idiopathic Hypersomnia Treatment Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Takeda Pharmaceutical Idiopathic Hypersomnia Treatment Product Portfolio Table 90. Takeda Pharmaceutical Recent Development Table 91. North America Idiopathic Hypersomnia Treatment Revenue by Type (2021-2026) & (US$ Million) Table 92. North America Idiopathic Hypersomnia Treatment Revenue by Type (2027-2032) & (US$ Million) Table 93. North America Idiopathic Hypersomnia Treatment Revenue by Application (2021-2026) & (US$ Million) Table 94. North America Idiopathic Hypersomnia Treatment Revenue by Application (2027-2032) & (US$ Million) Table 95. North America Idiopathic Hypersomnia Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 96. North America Idiopathic Hypersomnia Treatment Revenue by Country (2021-2026) & (US$ Million) Table 97. North America Idiopathic Hypersomnia Treatment Revenue by Country (US$ Million) & (2027-2032) Table 98. Europe Idiopathic Hypersomnia Treatment Revenue by Type (2021-2026) & (US$ Million) Table 99. Europe Idiopathic Hypersomnia Treatment Revenue by Type (2027-2032) & (US$ Million) Table 100. Europe Idiopathic Hypersomnia Treatment Revenue by Application (2021-2026) & (US$ Million) Table 101. Europe Idiopathic Hypersomnia Treatment Revenue by Application (2027-2032) & (US$ Million) Table 102. Europe Idiopathic Hypersomnia Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 103. Europe Idiopathic Hypersomnia Treatment Revenue by Country (2021-2026) & (US$ Million) Table 104. Europe Idiopathic Hypersomnia Treatment Revenue by Country (US$ Million) & (2027-2032) Table 105. China Idiopathic Hypersomnia Treatment Revenue by Type (2021-2026) & (US$ Million) Table 106. China Idiopathic Hypersomnia Treatment Revenue by Type (2027-2032) & (US$ Million) Table 107. China Idiopathic Hypersomnia Treatment Revenue by Application (2021-2026) & (US$ Million) Table 108. China Idiopathic Hypersomnia Treatment Revenue by Application (2027-2032) & (US$ Million) Table 109. Asia Idiopathic Hypersomnia Treatment Revenue by Type (2021-2026) & (US$ Million) Table 110. Asia Idiopathic Hypersomnia Treatment Revenue by Type (2027-2032) & (US$ Million) Table 111. Asia Idiopathic Hypersomnia Treatment Revenue by Application (2021-2026) & (US$ Million) Table 112. Asia Idiopathic Hypersomnia Treatment Revenue by Application (2027-2032) & (US$ Million) Table 113. Asia Idiopathic Hypersomnia Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 114. Asia Idiopathic Hypersomnia Treatment Revenue by Region (US$ Million) & (2021-2026) Table 115. Asia Idiopathic Hypersomnia Treatment Revenue by Region (US$ Million) & (2027-2032) Table 116. SAMEA Idiopathic Hypersomnia Treatment Revenue by Type (2021-2026) & (US$ Million) Table 117. SAMEA Idiopathic Hypersomnia Treatment Revenue by Type (2027-2032) & (US$ Million) Table 118. SAMEA Idiopathic Hypersomnia Treatment Revenue by Application (2021-2026) & (US$ Million) Table 119. SAMEA Idiopathic Hypersomnia Treatment Revenue by Application (2027-2032) & (US$ Million) Table 120. SAMEA Idiopathic Hypersomnia Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. SAMEA Idiopathic Hypersomnia Treatment Revenue by Country (2021-2026) & (US$ Million) Table 122. SAMEA Idiopathic Hypersomnia Treatment Revenue by Country (US$ Million) & (2027-2032) Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Idiopathic Hypersomnia Treatment Image Figure 2. Global Idiopathic Hypersomnia Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Idiopathic Hypersomnia Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Stimulant Medications Image Figure 5. Non-Stimulant Wake-Promoting Medications Image Figure 6. Sodium Oxybate Image Figure 7. Global Idiopathic Hypersomnia Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Idiopathic Hypersomnia Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 9. Retail Pharmacies Image Figure 10. Online Pharmacies Image Figure 11. Hospital Pharmacies Image Figure 12. Global Idiopathic Hypersomnia Treatment Market Size (US$ Million) & (2021-2032) Figure 13. Global Idiopathic Hypersomnia Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Idiopathic Hypersomnia Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Idiopathic Hypersomnia Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Idiopathic Hypersomnia Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Idiopathic Hypersomnia Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Idiopathic Hypersomnia Treatment Revenue Market Share by Type (2021-2032) Figure 20. Global Idiopathic Hypersomnia Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Idiopathic Hypersomnia Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Idiopathic Hypersomnia Treatment Revenue Market Share by Application (2021-2032) Figure 23. North America Idiopathic Hypersomnia Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Idiopathic Hypersomnia Treatment Revenue Share by Type (2021-2032) Figure 25. North America Idiopathic Hypersomnia Treatment Revenue Share by Application (2021-2032) Figure 26. North America Idiopathic Hypersomnia Treatment Revenue Share by Country (2021-2032) Figure 27. United States Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Idiopathic Hypersomnia Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Idiopathic Hypersomnia Treatment Revenue Share by Type (2021-2032) Figure 32. Europe Idiopathic Hypersomnia Treatment Revenue Share by Application (2021-2032) Figure 33. Europe Idiopathic Hypersomnia Treatment Revenue Share by Country (2021-2032) Figure 34. Germany Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Idiopathic Hypersomnia Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Idiopathic Hypersomnia Treatment Revenue Share by Type (2021-2032) Figure 44. China Idiopathic Hypersomnia Treatment Revenue Share by Application (2021-2032) Figure 45. Asia Idiopathic Hypersomnia Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Idiopathic Hypersomnia Treatment Revenue Share by Type (2021-2032) Figure 47. Asia Idiopathic Hypersomnia Treatment Revenue Share by Application (2021-2032) Figure 48. Asia Idiopathic Hypersomnia Treatment Revenue Share by Region (2021-2032) Figure 49. Japan Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Idiopathic Hypersomnia Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Idiopathic Hypersomnia Treatment Revenue Share by Type (2021-2032) Figure 57. SAMEA Idiopathic Hypersomnia Treatment Revenue Share by Application (2021-2032) Figure 58. SAMEA Idiopathic Hypersomnia Treatment Revenue Share by Country (2021-2032) Figure 59. Brazil Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Idiopathic Hypersomnia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Stimulant Medications
  • Non-Stimulant Wake-Promoting Medications
  • Sodium Oxybate
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Avadel Pharmaceuticals
  • BIOPROJET
  • Drive DeVilbiss Healthcare
  • Fisher and Paykel Healthcare
  • Jazz Pharmaceuticals
  • Theranexus
  • GlaxoSmithKline
  • Pfizer
  • Merck
  • Teva Pharmaceutical Industries
  • Takeda Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Idiopathic Hypersomnia Treatment Market by Type
  3. 1.2.1 Global Idiopathic Hypersomnia Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Stimulant Medications
  5. 1.2.3 Non-Stimulant Wake-Promoting Medications
  6. 1.2.4 Sodium Oxybate
  7. 1.3 Idiopathic Hypersomnia Treatment Market by Application
  8. 1.3.1 Global Idiopathic Hypersomnia Treatment Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Retail Pharmacies
  10. 1.3.3 Online Pharmacies
  11. 1.3.4 Hospital Pharmacies
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Idiopathic Hypersomnia Treatment Market Dynamics
  1. 2.1 Idiopathic Hypersomnia Treatment Industry Trends
  2. 2.2 Idiopathic Hypersomnia Treatment Industry Drivers
  3. 2.3 Idiopathic Hypersomnia Treatment Industry Opportunities and Challenges
  4. 2.4 Idiopathic Hypersomnia Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Idiopathic Hypersomnia Treatment Market Perspective (2021-2032)
  2. 3.2 Global Idiopathic Hypersomnia Treatment Growth Trends by Region
  3. 3.2.1 Global Idiopathic Hypersomnia Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Idiopathic Hypersomnia Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Idiopathic Hypersomnia Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Idiopathic Hypersomnia Treatment Revenue by Players
  2. 4.1.1 Global Idiopathic Hypersomnia Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Idiopathic Hypersomnia Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Idiopathic Hypersomnia Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Idiopathic Hypersomnia Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Idiopathic Hypersomnia Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Idiopathic Hypersomnia Treatment Players, Product Type & Application
  8. 4.5 Global Idiopathic Hypersomnia Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Idiopathic Hypersomnia Treatment Market CR5 and HHI
  11. 4.6.3 2025 Idiopathic Hypersomnia Treatment Tier 1, Tier 2, and Tier 3
5 Idiopathic Hypersomnia Treatment Market Size by Type
  1. 5.1 Global Idiopathic Hypersomnia Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Idiopathic Hypersomnia Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Idiopathic Hypersomnia Treatment Revenue Market Share by Type (2021-2032)
6 Idiopathic Hypersomnia Treatment Market Size by Application
  1. 6.1 Global Idiopathic Hypersomnia Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Idiopathic Hypersomnia Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Idiopathic Hypersomnia Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Avadel Pharmaceuticals
  2. 7.1.1 Avadel Pharmaceuticals Company Information
  3. 7.1.2 Avadel Pharmaceuticals Business Overview
  4. 7.1.3 Avadel Pharmaceuticals Idiopathic Hypersomnia Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Avadel Pharmaceuticals Idiopathic Hypersomnia Treatment Product Portfolio
  6. 7.1.5 Avadel Pharmaceuticals Recent Developments
  7. 7.2 BIOPROJET
  8. 7.2.1 BIOPROJET Company Information
  9. 7.2.2 BIOPROJET Business Overview
  10. 7.2.3 BIOPROJET Idiopathic Hypersomnia Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 BIOPROJET Idiopathic Hypersomnia Treatment Product Portfolio
  12. 7.2.5 BIOPROJET Recent Developments
  13. 7.3 Drive DeVilbiss Healthcare
  14. 7.3.1 Drive DeVilbiss Healthcare Company Information
  15. 7.3.2 Drive DeVilbiss Healthcare Business Overview
  16. 7.3.3 Drive DeVilbiss Healthcare Idiopathic Hypersomnia Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Drive DeVilbiss Healthcare Idiopathic Hypersomnia Treatment Product Portfolio
  18. 7.3.5 Drive DeVilbiss Healthcare Recent Developments
  19. 7.4 Fisher and Paykel Healthcare
  20. 7.4.1 Fisher and Paykel Healthcare Company Information
  21. 7.4.2 Fisher and Paykel Healthcare Business Overview
  22. 7.4.3 Fisher and Paykel Healthcare Idiopathic Hypersomnia Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Fisher and Paykel Healthcare Idiopathic Hypersomnia Treatment Product Portfolio
  24. 7.4.5 Fisher and Paykel Healthcare Recent Developments
  25. 7.5 Jazz Pharmaceuticals
  26. 7.5.1 Jazz Pharmaceuticals Company Information
  27. 7.5.2 Jazz Pharmaceuticals Business Overview
  28. 7.5.3 Jazz Pharmaceuticals Idiopathic Hypersomnia Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Jazz Pharmaceuticals Idiopathic Hypersomnia Treatment Product Portfolio
  30. 7.5.5 Jazz Pharmaceuticals Recent Developments
  31. 7.6 Theranexus
  32. 7.6.1 Theranexus Company Information
  33. 7.6.2 Theranexus Business Overview
  34. 7.6.3 Theranexus Idiopathic Hypersomnia Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Theranexus Idiopathic Hypersomnia Treatment Product Portfolio
  36. 7.6.5 Theranexus Recent Developments
  37. 7.7 GlaxoSmithKline
  38. 7.7.1 GlaxoSmithKline Company Information
  39. 7.7.2 GlaxoSmithKline Business Overview
  40. 7.7.3 GlaxoSmithKline Idiopathic Hypersomnia Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 GlaxoSmithKline Idiopathic Hypersomnia Treatment Product Portfolio
  42. 7.7.5 GlaxoSmithKline Recent Developments
  43. 7.8 Pfizer
  44. 7.8.1 Pfizer Company Information
  45. 7.8.2 Pfizer Business Overview
  46. 7.8.3 Pfizer Idiopathic Hypersomnia Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Pfizer Idiopathic Hypersomnia Treatment Product Portfolio
  48. 7.8.5 Pfizer Recent Developments
  49. 7.9 Merck
  50. 7.9.1 Merck Company Information
  51. 7.9.2 Merck Business Overview
  52. 7.9.3 Merck Idiopathic Hypersomnia Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Merck Idiopathic Hypersomnia Treatment Product Portfolio
  54. 7.9.5 Merck Recent Developments
  55. 7.10 Teva Pharmaceutical Industries
  56. 7.10.1 Teva Pharmaceutical Industries Company Information
  57. 7.10.2 Teva Pharmaceutical Industries Business Overview
  58. 7.10.3 Teva Pharmaceutical Industries Idiopathic Hypersomnia Treatment Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Teva Pharmaceutical Industries Idiopathic Hypersomnia Treatment Product Portfolio
  60. 7.10.5 Teva Pharmaceutical Industries Recent Developments
  61. 7.11 Takeda Pharmaceutical
  62. 7.11.1 Takeda Pharmaceutical Company Information
  63. 7.11.2 Takeda Pharmaceutical Business Overview
  64. 7.11.3 Takeda Pharmaceutical Idiopathic Hypersomnia Treatment Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Takeda Pharmaceutical Idiopathic Hypersomnia Treatment Product Portfolio
  66. 7.11.5 Takeda Pharmaceutical Recent Developments
8 North America
  1. 8.1 North America Idiopathic Hypersomnia Treatment Revenue (2021-2032)
  2. 8.2 North America Idiopathic Hypersomnia Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Idiopathic Hypersomnia Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Idiopathic Hypersomnia Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Idiopathic Hypersomnia Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Idiopathic Hypersomnia Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Idiopathic Hypersomnia Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Idiopathic Hypersomnia Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Idiopathic Hypersomnia Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Idiopathic Hypersomnia Treatment Revenue by Country
  11. 8.6.1 North America Idiopathic Hypersomnia Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Idiopathic Hypersomnia Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Idiopathic Hypersomnia Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Idiopathic Hypersomnia Treatment Revenue (2021-2032)
  2. 9.2 Europe Idiopathic Hypersomnia Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Idiopathic Hypersomnia Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Idiopathic Hypersomnia Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Idiopathic Hypersomnia Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Idiopathic Hypersomnia Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Idiopathic Hypersomnia Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Idiopathic Hypersomnia Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Idiopathic Hypersomnia Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Idiopathic Hypersomnia Treatment Revenue by Country
  11. 9.6.1 Europe Idiopathic Hypersomnia Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Idiopathic Hypersomnia Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Idiopathic Hypersomnia Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Idiopathic Hypersomnia Treatment Revenue (2021-2032)
  2. 10.2 China Idiopathic Hypersomnia Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Idiopathic Hypersomnia Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Idiopathic Hypersomnia Treatment Revenue by Type (2027-2032)
  5. 10.3 China Idiopathic Hypersomnia Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Idiopathic Hypersomnia Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Idiopathic Hypersomnia Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Idiopathic Hypersomnia Treatment Revenue by Application (2027-2032)
  9. 10.5 China Idiopathic Hypersomnia Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Idiopathic Hypersomnia Treatment Revenue (2021-2032)
  2. 11.2 Asia Idiopathic Hypersomnia Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Idiopathic Hypersomnia Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Idiopathic Hypersomnia Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Idiopathic Hypersomnia Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Idiopathic Hypersomnia Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Idiopathic Hypersomnia Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Idiopathic Hypersomnia Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Idiopathic Hypersomnia Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Idiopathic Hypersomnia Treatment Revenue by Country
  11. 11.6.1 Asia Idiopathic Hypersomnia Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Idiopathic Hypersomnia Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Idiopathic Hypersomnia Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Idiopathic Hypersomnia Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Idiopathic Hypersomnia Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Idiopathic Hypersomnia Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Idiopathic Hypersomnia Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Idiopathic Hypersomnia Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Idiopathic Hypersomnia Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Idiopathic Hypersomnia Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Idiopathic Hypersomnia Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Idiopathic Hypersomnia Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Idiopathic Hypersomnia Treatment Revenue by Country
  11. 12.6.1 SAMEA Idiopathic Hypersomnia Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Idiopathic Hypersomnia Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Idiopathic Hypersomnia Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst